Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuangli Bio-Tech Holdings CoTPE:6431 -2.49%65 Debt-to-Equity is 0.91 as of Mar. 2026, which is 60% above its 10-year median of 0.57. GuruFocus rates TPE:6431 with a GF Score™ of 65/100 and a GF Value™ of NT$10.61 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,756 Consumer Packaged Goods companies, Kuangli Bio-Tech Holdings Co ranks worse than 75.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kuangli Bio-Tech Holdings Co's Debt-to-Equity or its related term are showing as below:
TPE:6431'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.57 Max: 0.91
Current: 0.91
During the past 13 years, the highest Debt-to-Equity Ratio of Kuangli Bio-Tech Holdings Co was 0.91. The lowest was 0.01. And the median was 0.57.
TPE:6431's Debt-to-Equity is ranked worse than 75.34% of 1756
companies
in the Consumer Packaged Goods industry
Industry Median: 0.42
vs TPE:6431: 0.91
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kuangli Bio-Tech Holdings Co Debt-to-Equity Related Terms
Kuangli Bio-Tech Holdings Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Kuangli Bio-Tech Holdings Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuangli Bio-Tech Holdings Co Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Kuangli Bio-Tech Holdings Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kuangli Bio-Tech Holdings Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuangli Bio-Tech Holdings Co (TPE:6431) has a Debt-to-Equity of 0.91 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. This is 60% above median its historical median of 0.57. Over the past decade, Kuangli Bio-Tech Holdings Co's Debt-to-Equity has ranged from 0.01 to 0.91. According to the industry distribution chart, Kuangli Bio-Tech Holdings Co ranks #1323 out of 1756 companies in the Consumer Packaged Goods industry, placing it in the top 75.3%.
Is Kuangli Bio-Tech Holdings Co's Debt-to-Equity too high?
Kuangli Bio-Tech Holdings Co's current Debt-to-Equity of 0.91 is 60% above median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.91. The Consumer Packaged Goods industry median Debt-to-Equity is 0.42. Kuangli Bio-Tech Holdings Co's value of 0.91 is 116.7% above this industry median. Based on the distribution chart, Kuangli Bio-Tech Holdings Co ranks #1323 out of 1756 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's Debt-to-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Kuangli Bio-Tech Holdings Co ranks #1323 out of 1756 companies for Debt-to-Equity. This places Kuangli Bio-Tech Holdings Co in the lower half of its industry. The industry median Debt-to-Equity is 0.42. Kuangli Bio-Tech Holdings Co's value of 0.91 is 116.7% above this benchmark. Historically, Kuangli Bio-Tech Holdings Co's own Debt-to-Equity has ranged from 0.01 to 0.91 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.42, Kuangli Bio-Tech Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.42, based on 1,756 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuangli Bio-Tech Holdings Co's current Debt-to-Equity of 0.91 is 116.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuangli Bio-Tech Holdings Co's current Debt-to-Equity is 0.91, which is 60% above median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$10.61, compared to a current price of NT$19.60 — trading 84.7% above its estimated fair value. The current Debt-to-Equity is 0.91, which is 60% above median its 10-year median of 0.57 and 116.7% above the Consumer Packaged Goods industry median of 0.42. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current Debt-to-Equity is 0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued.
The current stock price of NT$19.60 is trading 84.7% above its estimated GF Value™ of NT$10.61.
GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.
Key valuation signals for TPE:6431:
Debt-to-Equity: 0.91 (60% above median its 10-year median of 0.57)
GF Value™: NT$10.61 vs. price of NT$19.60 (84.7% above fair value)
Industry Position: 116.7% above the Consumer Packaged Goods median (#1323 of 1756)
No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
65GF Score
Get the complete analysis for TPE:6431
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6431 has been successfully added to your 
